Assessing Patient Response to Bronchodilator Therapy

**Purpose**
To establish a baseline function and reveal the presence or absence of a desired response to bronchodilator therapy in non-ventilated patients.

**Audience**
A licensed respiratory care practitioner may perform pulmonary function monitoring.

**Scope**
All non-intubated patients receiving bronchodilator therapy by RCS will be assessed by measuring peak expiratory flow and/or (FEV\textsubscript{1}) before and after a treatment if ordered by a physician. These outcomes are to be documented in Epic under Respiratory Care. When possible, these outcomes should be compared to predicted values for a person of the same sex, age, and height and documented as part of the assessment.

**Indications**
Assessment of airflow and other clinical monitoring is indicated when the need exists
- To confirm the appropriateness of therapy
- To individualize the patient’s medication dosage and/or frequency of administration for each treatment
- To help determine patient status during acute and long-term pharmacologic therapy
- To determine the need for a change in dosage, medication, or frequency of therapy

**Contra-indications**
There are no absolute contraindications. However, when patients are in acute severe distress, the screening should be performed after bronchodilator therapy has been instituted.

**Relative Contra-indications**
Relative contraindications are conditions in which pulmonary function monitoring may be inappropriate secondary to patient physical or performance related limitations (i.e., maxillo-facial deformity, trauma, surgical intervention, or an inability to follow commands necessary to perform procedure as directed).

**Equipment**
- Peak Flow Meter
- Bedside pulmonary function screening device.
- Disposable Pneumotach.
- Nose clip if necessary
- Lung function calculator

Continued next page
Assessing Patient Response to Bronchodilator Therapy

Corresponding Policies
- Respiratory Care Services Policy # 7.2.6; Spirometry.

References